This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years. Research Beam Model: Research Beam Product ID: 14341 12800 USD New
Competing in the European Molecular Diagnostics Market:France, Germany, Italy, Spain, UK

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Competing in the European Molecular Diagnostics Market:France, Germany, Italy, Spain, UK

 
 
 

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.



This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.



The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods.



In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.  



Table of Contents



I.       Introduction



II.      Worldwide Technology and Market Overview



          A.  DNA Sequencing 

              

          B.  DNA and RNA Probes Technology 

              

          C.  Detection Technologies 

              

          D.  Instrumentation Review 

                        

          E.  Biochips: Genosensors, Microarrays, and Labs-on-the-Chip



          F.  Pharmacogenomics



          G.  Major Applications



III.     France



IV.     Germany



V.      Italy



VI.     Spain



VII.    U.K.



VIII.   Major Product Development Opportunities



IX.     Design Criteria for Decentralized Testing Products



X.      Alternative Market Penetration Strategies



XI.     Potential Market Entry Barriers and Risks



XII.    Competitive Assessments



XIII.   Appendix 

                                                                                            

Contains 970 pages and 75 tables